Literature DB >> 18852008

Immunogenicity of recombinant protective antigen and efficacy against intranasal challenge with Bordetella bronchiseptica.

Zhanqin Zhao1, Yun Xue, Xibiao Tang, Bin Wu, Xiangchao Cheng, Qigai He, Chunjie Zhang, Aizhen Guo, Meilin Jin, Huanchun Chen.   

Abstract

Bordetella bronchiseptica is a Gram-negative respiratory pathogen that causes substantial disease in a variety of animals. Filamentous hemagglutinin (FHA) and pertactin are important attachment factors and protective immunogens, which serve as protective antigens in several animal models of infection with B. bronchiseptica. Here, we showed the efficacy of subcutaneous immunization of mice with a recombinant protein rF1P2, which consisted of the important immunodominant protective type I domain (F1) of FHA and the highly immunogenic region II domain (P2) of pertactin. Groups of mice tested, when challenged with different strains of B. bronchiseptica were fully protected, with long-lasting immunity to lethal B.bronchiseptica challenge, whereas mice immunized with Freund's adjuvant alone or PBS were not. In rF1P2-immunized mice, specific antibodies lasted for more than 120 days, and the IgG1/IgG2a ratio remained at a constant level till the end of the study. This suggests that rF1P2-induced a long-lasting balanced humoral immune responses and immunological memory in mice. rF1P2-specific antisera inhibited hemagglutination associated with full-length mature FHA. Furthermore, passive antiserum transfer from immunized animals completely protected naive mice from subsequent B. bronchiseptica challenge. These data may have implications for the development of safe and efficacious subunit vaccines for the prevention of bordetellosis, and may contribute to future acellular whooping cough vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852008     DOI: 10.1016/j.vaccine.2008.09.091

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.

Authors:  D Bottero; M E Zurita; M E Gaillard; E Bartel; C Vercellini; D Hozbor
Journal:  Appl Environ Microbiol       Date:  2018-01-31       Impact factor: 4.792

2.  Immunologic study and optimization of Salmonella delivery strains expressing adhesin and toxin antigens for protection against progressive atrophic rhinitis in a murine model.

Authors:  Jin Hur; Hoyeon Byeon; John Hwa Lee
Journal:  Can J Vet Res       Date:  2014-10       Impact factor: 1.310

3.  Immuno-proteomics analysis between OMV of vaccine and dominant wild type strains of Bordetella pertussis in Iran.

Authors:  Ali Badamchi; Fariborz Bahrami; Alireza Hadizadeh Tasbiti; Shamsi Yari; Morvarid Shafiei; Fereshteh Shahcheraghi; Seyed Davar Siadat
Journal:  Iran J Microbiol       Date:  2020-04

4.  A Marker-Free Bordetella bronchiseptica aroA/bscN Double Deleted Mutant Confers Protection Against Lethal Challenge.

Authors:  Weicheng Ai; Zhong Peng; Fei Wang; Yue Zhang; Sisi Xie; Wan Liang; Lin Hua; Xiangru Wang; Huanchun Chen; Bin Wu
Journal:  Vaccines (Basel)       Date:  2019-11-04

5.  Immune efficacy of five novel recombinant Bordetella bronchiseptica proteins.

Authors:  Yan Liu; Hui Chen; Qiang Wei; Chenwen Xiao; Quanan Ji; Guolian Bao
Journal:  BMC Vet Res       Date:  2015-07-30       Impact factor: 2.741

6.  Antibodies induced by oral immunization of mice with a recombinant protein produced in tobacco plants harboring Bordetella pertussis epitopes.

Authors:  Karla Sanchez-Alvarez; Sergio Rosales-Mendoza; Karen L Reyes-Barrera; Leticia Moreno-Fierros; Ruth E Soria-Guerra; Rosalba Castillo-Collazo; Elizabeth Monreal-Escalente; Angel G Alpuche-Solis
Journal:  Plant Cell Tissue Organ Cult       Date:  2021-07-10       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.